futibatinib
Sign in to saveAlso known as 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one
Futibatinib, sold under the brand name Lytgobi, is an anti-cancer medication used for the treatment of cholangiocarcinoma (bile duct cancer). It is a kinase inhibitor. It is taken by mouth.
~1 min read
Encyclopedic overview
5 sectionsContents
- Medical uses
- Society and culture
- Legal status
- Names
- References
Futibatinib, sold under the brand name Lytgobi, is an anti-cancer medication used for the treatment of cholangiocarcinoma (bile duct cancer). It is a kinase inhibitor. It is taken by mouth.
Futibatinib was approved for medical use in the United States in September 2022, in Japan in June 2023 and in the European Union in July 2023.
Excerpted from Wikipedia’s “futibatinib” article, available under the CC BY-SA 4.0 licence.